Introduction
It is no mystery that, when we as surgeons make clinical decisions, we rely on previous experience as well as available scientific evidence. Our experience develops from the understanding of the pathophysiology of a disease and the introduction of procedures to alter the process. Scientific evidence becomes available when close observations of the results of the procedure are reported. 1 In the surgical literature, these reports have typically consisted of case reports (arbitrarily defined as 10 or fewer subjects) and case series.
Design of the study
A study design is complex and involves a number of decisions. The most fundamental is whether to stand apart from the events taking place in the study subjects (in an observational study), or to test the effects of an intervention on these events (in an experiment). 2 Case series and case control series are examples of observational studies. Cohort studies and randomized controlled trials are interventional studies. The randomized controlled trial is the only study design that must be prospective, while all others can be designed as retrospective or prospective studies (Table 1) . With observational designs, the measurements can be done on a single occasion (crosssectional study) or over a period of time (longitudinal study).
Levels of evidence
There are several grading systems for assessing the level of evidence provided by a study. 3, 4 The first was developed by the Canadian Task Force on the Periodic Health Examination in Randomized Clinical Surgical Trials: Are They Really Necessary? the 1970s ( Table 2) and was adopted by the US Task Force. While differing in some respects, most systems consider the a priori design of the study and the actual quality of the study. In the hierarchy of study design classification, the case series is the weakest in determining the effectiveness of treatment (level 3), while a randomized controlled trial will provide the best evidence (level 1) when properly executed.
Randomized clinical trial
Controlled clinical trials are randomized, prospective studies designed to evaluate the effectiveness of new treatments and procedures. Patients are randomly assigned to intervention and control groups. Usually, the control group receives the standard treatment, or, in some trials, a placebo. Some studies are designed to evaluate more than one experiment or alternative treatment, and patients are randomized to more than one treatment arm. After treatment is administered, the groups are compared on outcomes of intent, such as mortality, morbidity and change in patient function status. A very important aspect of randomized clinical trials is adherence to the Declaration of Helsinki of 1964 and compliance with regulatory human research requirements (Good Clinical Practice guidelines). 
Timing of a randomized clinical trial
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■ ITANI AND McCULLOUGH ■ eral factors. Before conducting a trial, an investigator needs to have the necessary knowledge and tools, and know something about the safety of the intervention, outcomes to assess, and the techniques to do so. Conducting clinical trials of adequate magnitude is costly and should be done only when preliminary evidence of the efficacy of an intervention looks promising enough to warrant the effort and expense involved or there is disagreement in the clinical community about comparative safety and efficacy.
When a new surgical technique is in development, it is probably too early to conduct a large randomized trial. The technique may be in a period of rapid refinement. There is also likely to be a relatively small number of surgeons who can perform the procedure. There may not be preliminary safety or efficacy data to justify subjecting a large number of people to the procedure. On the other hand, once a procedure has gained widespread acceptance, it may be too late to conduct a randomized study. Between these two extremes, a promising treatment emerges, surgeons and patients become familiar with the technique, and safety and efficacy data accumulate, usually from case reports, case series and small studies. At some point in this process, the general perception of the usefulness of the emerging treatment is in a state of equipoise, that is, opposing viewpoints are held in balance and there is general consensus that the efficacy and safety of the new treatment in comparison with existing treatments remains an open question. At this time, justification for a randomized clinical trial is strongest. 5 In practice, though, it may be difficult at this time to find surgeons whose opinion is truly in equipoise. While equipoise may exist among the community of surgeons, that is, half believing the treatment is effective, half believing it is not, individual surgeons may have a definite preference and may be unwilling to randomize patients to what they consider an inferior treatment. Even so, the window of time during which equipoise exists is the optimal time to conduct the randomized trial. 6
Ethics of randomized trials
People have debated the ethics of clinical trials for as long as they have been done. The arguments have changed over the years and, perhaps, have become more sophisticated. 7 Ethical issues centre in general around a physician's obligations to his/her patient versus societal good, informed consent, randomization, the use of placebo-control groups, and the inclusion of women, children, the elderly and minorities. 8, 9 Studies that require intervention in vulnerable populations, especially those with diminished ability to make decisions about participation, raise important ethical issues about the protection or overprotection of such populations. 10 Studies that continue to enrol participants after trends in the data have appeared have raised some of the controversy which, increasingly, is being managed by setting up data and safety monitoring committees. 11, 12 A well-designed trial can answer important public health questions without impairing the welfare of individuals. There may, at times, be conflicts between a physician's perception of what is good for his/her patient and the needs of the trial. In such instances, the needs of the participants should predominate. Study design, especially sample-size determination, needs to take this clinical ethical concern into account.
Proper informed consent is essential and has been so at 14, 15 underscoring the need for sustained attention not just to the informed consent form but also to the overall informed consent process. In many clinical trial settings, though, true informed consent can be obtained. The situations where participant enrolment must be done immediately, in comatose patients, or in highly stressful circumstances and where the prospective participants are minors or not fully competent to understand the study, are more complicated and may not have optimal solutions. 5 Randomization has generally been more of a problem for physicians and investigators than for participants, 16 because chance assignment of treatment would not be acceptable as the standard of care in clinical practice. The obligation to random assignment should only apply if the investigator does not believe that a preferred therapy exists. If the physician does believe reliably that there is a preferred treatment, then that physician should not participate in the trial. On the other hand, if the investigator truly cannot say that one treatment is better than another, there should be no ethical problem with randomization. Such judgements regarding efficacy obviously vary among investigators. As it may be unreasonable to expect that an individual investigator has no preference, not only at the start of a trial but during its conduct, the concept of "clinical equipoise" has been proposed. 17 In this concept, the presence of uncertainty as to the benefits or harm from an intervention among the expert medical community, rather than of the individual investigator, is justification for a clinical trial. Similarly, the use of a placebo is acceptable if there is no known best therapy and in other special circumstances (e.g. the commonly used therapy is poorly tolerated). 18 Of course, all participants must be told that there is a specified probability, for example, 50%, of receiving placebo. The use of a placebo also does not imply that control group participants will receive no treatment. In many trials, the objective is to see whether a new intervention plus standard care is better or worse than a placebo plus standard care. In all trials, there is the ethical obligation to allow the best standard care to be used. 7 It is also important to emphasize that confidence in the integrity of the trial and its results is essential to every trial. If, through intent and/or inadvertent actions, that confidence is impaired, not only have the participants and, potentially, others in the community been harmed, the trial loses it rationale and ability to influence science and medical practice. 7
Limitations of randomized clinical trials
Randomized clinical trials tend to take a long time to complete because of the time required for planning, accruing and following patients, and analysing results. As a consequence, results may not be available for many years. Clinical trials are also expensive to perform, although their costs may be recuperated if ineffective treatments are abandoned and effective treatments are implemented. 19 The results of a randomized clinical trial may not be generalizable or applicable to all patients with the disease because of the strict inclusion and exclusion criteria and inherent differences in patients who volunteer for trials. In addition, not all patients will respond similarly to treatment. Another limitation is that in situations where the disease or outcome is rare or only occurs after a long period of follow-up, randomized clinical trials are difficult or not feasible. Also, as discussed above, the ethics of performing a randomized clinical trial are controversial and some clinicians may feel uncomfortable with randomizing their patients when they believe one treatment to be superior, even if that is based only on anecdotal evidence. In randomized trials, there are also issues of special concern unique to surgical trials. 20 The issue of standardization of the procedure is of major importance in surgical trials. Standardization is difficult because surgeons may vary in their experience with and ability to perform a surgical technique, there may be individual preferences in performing the procedure, and technical modifications may occur as the procedure evolves. Moreover, differences in perioperative and postoperative care may also have an impact on the outcome. There are two issues related to standardization of the procedure. First, there is the issue of who should perform the procedure -experts only or surgeons of varying ability. Second, there is the issue of standardization of the procedure so that it is performed similarly by all surgical participants and it can be duplicated following publication of the trial results. The implications of these two issues are different and strategies to address them differ. 21 The first issue is analogous to assessing compliance in a medical trial. Thus, if the procedure is performed by experts only in a very controlled fashion, this is analogous to an efficacy trial. The advantage of such a trial is that if the procedure is truly superior to the other intervention, then this design has the greatest likelihood of detecting a difference.
070/20
■ ITANI AND McCULLOUGH ■ The disadvantage obviously is that the results are less generalizable. Like most issues in clinical trials, there is no right or wrong answer. 21 No matter how many surgeons are involved in the trial and that investigators want to mimic routine practice, there must be at least a certain amount of standardization so that readers of the trial results can understand what was done and can duplicate the procedure in their own practice. There are several strategies to ensure a minimum standard. First, all surgeons should agree on the performance of the critical aspects of the procedure. It may not be necessary to have agreement with all of the technical aspects, but there should be consensus on those that are deemed important. Furthermore, if there are aspects of the perioperative and postoperative care that have an impact on outcome, they should be standardized. Teaching sessions may be held preoperatively and feedback given to surgeons on their performance during the trial. In addition, obtaining documentation that the procedure has been performed satisfactorily may contribute to ensuring that the surgery is performed adequately. Finally, patients are usually stratified according to surgeon or centre to ensure balance in case there are differences in surgical technique between centres or surgeons.
Blinding is often a difficult issue in surgical trials. It may not be an issue if two surgical procedures are being compared. There is often a placebo effect of surgery. Performing sham operations might be ethically difficult but not unfeasible. The lack of blinding is especially worrisome if the primary outcome is a change in symptoms or quality of life rather than a hard outcome measure such as mortality or morbidity. In these situations, if a hard outcome measure is also used and it correlates with the patient assessment, there is less concern about the possibility of bias. An independent assessor who is unaware of the treatment group that the patient is in may perform assessments. If criteria used to define an outcome are explicitly specified a priori, it may minimize or eliminate bias. Investigators may also choose, in this situation, to have a blinded panel review the results of tests to ensure that they meet the criteria.
Finally, patient issues may be of greater concern in surgical trials. In a medical trial, patients may be randomized to either treatment arm with the possibility that, at the conclusion of the trial, they can receive the more efficacious treatment if the disease is not progressive and the treatment is reversible. Surgical procedures, however, are almost always permanent. This may be of particular concern if a medical therapy is being compared to a surgical procedure and the procedures differ in their magnitude or invasiveness. Patients may have a prefer-ence for one or the other treatment and, therefore, refuse to participate in the trial. There also tends to be more emotion involved with surgery, and patients may be less willing to leave to chance the decision as to which procedure will be performed. Surgeons themselves may feel uncomfortable in discussing the uncertainty of randomization with patients requiring surgery. 22 Thus, accruing patients for surgical trials may be more difficult than for medical trials.
Study protocol
Every well-designed clinical trial requires a protocol. The study protocol can be viewed as a written agreement between the investigator, the participant and the scientific community. 7 The protocol provides the background, specifies the objectives, and describes the design and organization of the trial. Every detail explaining how the trial is carried out does not need to be included, provided that there is a comprehensive manual of procedures that contains such information. The protocol serves as a document to assist communication among those working in the trial.
The protocol should be developed before the beginning of participant enrolment and should remain essentially unchanged except perhaps for minor updates. Careful thought and justification should go into any changes.
Statistical power and the planning of clinical trials
Investigators use power analysis to determine the probability that a given study will reject the null hypothesis when it is, in fact, false. In other words, power analysis determines the chance of detecting a true positive result. By tradition, researchers consider a study to be adequately powered if it has at least an 80% chance of detecting a clinically significant effect when one exists. This exact value is arbitrary; higher power will always be preferable and should be set with consideration of the importance of limiting both false-negative (i.e. type 2 errors) and false-positive conclusions (i.e. type 1 errors). 23 To calculate a study's power to detect a given effect, investigators use a set of other variables, including the number of individuals to be enrolled, the expected variability of their outcomes, and the chosen probability of making a type 1 error. Reformulating these variables allows one to calculate the number of study participants needed to detect a clinically important effect size with acceptable power. Although consensus among reasonable clinicians will generally enable
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■ RANDOMIZED CLINICAL SURGICAL TRIALS ■ determinations of how small an effect would be clinically important to detect, disagreement about this value may occasionally emerge. In such cases, a three-tiered, hierarchical approach for investigators to use the effect size to be entered into sample size calculations is advocated. 23 First, when empirical definitions of clinically meaningful effects exist, such as in the percentage reduction of reported pain necessary to define analgesic efficacy, 24 those values ought to be used. Second, if there is neither clinical consensus nor empirical evidence to guide definitions of clinically important effects, but data from earlier trials or observational studies reliably indicate an intervention's plausible effect, this value may be used. Finally, if none of the foregoing criteria are met, then previously published definitions of moderate effect sizes such as those described by Cohen should be used. 25 Trials that cannot reliably detect effect sizes defined using this hierarchical approach may be defined as underpowered. 23 Holpern et al conclude that underpowered trials are ethical in only two situations: 23 small trials of interventions for rare diseases in which investigators document explicit plans for including their results with those of similar trials in a prospective metaanalysis, and early-phase trials in the development of drugs or devices, provided they are adequately powered for defined purposes other than randomized treatment comparisons. In both cases, investigators must inform prospective subjects that their participation may only indirectly contribute to future health care benefits.
Conclusions
There is certainly a perception held by others that surgeons are not adequately assessing surgical procedures. 21, 26 In an editorial in the Lancet in 1996, entitled, "Surgical research or comic opera: questions, but few answers", Richard Horton criticized surgeons for their high reliance on case studies and stated that, if surgeons wished to retain their academic reputation, they must find imaginative ways to collaborate with epidemiologists to improve the design of the case series and to plan randomized trials. 27 Furthermore, he quoted a medical statistician, Major Greenwell, who stated, "I should like to shame surgeons out of comic opera performances which they suppose are statistics of operations." 27 This quote dates back to 1923. In a similar condemnation, Spodick complained of "the repeated reporting of biased data from uncontrolled or poorly controlled trials, giving an illusion of success due to sheer quantity but that a thousand zeros look impressive on paper, but they still amount to zero". 27 With increasing pressure from government, third-party payers and even patients, there will be greater emphasis to make therapeutic decisions on the basis of sounder evidence. Thus, we must look at ways to overcome methodological and feasibility problems and perform high-quality randomized controlled trials addressing important clinical issues. In those situations where it is deemed unfeasible to perform a randomized controlled trial, we need to look at alternatives that may be less rigorous than the randomized controlled trial, such as analytical case-controlled or cohort studies, but more rigorous than uncontrolled descriptive case series or cross-sectional studies. 20 The goal should be to bring surgical innovation and development up to the standards of evidence-based medicine, to which surgical research makes an essential contribution.
